Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Hits New 52-Week Low – Time to Sell?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)’s stock price reached a new 52-week low during trading on Wednesday . The stock traded as low as $20.94 and last traded at $21.1050, with a volume of 719422 shares. The stock had previously closed at $21.95.

Analyst Ratings Changes

Several equities analysts recently weighed in on FMS shares. The Goldman Sachs Group downgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research report on Tuesday. Truist Financial set a $28.00 price target on Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. UBS Group downgraded Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research note on Wednesday, October 15th. Bank of America downgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research note on Wednesday, October 15th. Finally, Wall Street Zen raised shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Four investment analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, Fresenius Medical Care AG & Co. KGaA has an average rating of “Reduce” and an average target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Trading Down 3.8%

The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 0.45. The stock has a fifty day simple moving average of $23.33 and a 200 day simple moving average of $24.96. The firm has a market capitalization of $12.39 billion, a P/E ratio of 15.41, a PEG ratio of 0.70 and a beta of 0.90.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a return on equity of 7.42% and a net margin of 3.72%.The firm had revenue of $5.73 billion during the quarter, compared to analyst estimates of $4.72 billion. As a group, research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 49.6% during the third quarter. JPMorgan Chase & Co. now owns 56,252 shares of the company’s stock valued at $1,481,000 after buying an additional 18,642 shares during the last quarter. CIBC Private Wealth Group LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after acquiring an additional 1,103 shares in the last quarter. Kestra Private Wealth Services LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 16.7% in the 3rd quarter. Kestra Private Wealth Services LLC now owns 13,640 shares of the company’s stock valued at $359,000 after acquiring an additional 1,955 shares during the last quarter. Virtus Advisers LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA in the 3rd quarter valued at $290,000. Finally, Qube Research & Technologies Ltd lifted its stake in Fresenius Medical Care AG & Co. KGaA by 11.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 223,222 shares of the company’s stock worth $5,877,000 after purchasing an additional 23,659 shares in the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.